Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, City Of Hope National Medical Center, City of Hope, Fred Hutch Cancer Center, University of Alabama at Birmingham, The Alfred Hospital, Monash University, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Amgen (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2987573142